You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 293 No. 1, January 5, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Nutritional and Metabolic Disorders
 •Lipids and Lipid Disorders
 •Cardiovascular System
 •Cardiovascular Disease/ Myocardial Infarction
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

High-Dose Statins in Acute Coronary Syndromes

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Although 2 randomized controlled trials previously evaluated the effect of early initiation of aggressive statin therapy following an acute coronary syndrome (ACS) event,1-2 the A to Z trial reported by Dr de Lemos and colleagues3 is the first randomized controlled trial to evaluate a strategy of early initiation of treatment with a statin compared with a delayed approach. The impact of any comparison of early with delayed initiation (intensive or not) in the carefully designed and controlled setting of a clinical trial is likely to be different in clinical practice. Several studies have shown that the practice of delayed initiation of lipid-lowering medications is not as effective as early initiation with regard to patient adherence to long-term therapy and the achievement of target national cholesterol guideline goals.4-5 There is a high likelihood that individuals intended to have delayed initiation would actually never be treated with statins, exposing . . . [Full Text of this Article]

Bruce Ovbiagele, MD
ovibes@mednet.ucla.edu
Stroke Center and Department of Neurology
University of California
Los Angeles



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

High-Dose Statins in Acute Coronary Syndromes
John R. Crouse, III
JAMA. 2005;293(1):36.
EXTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes
Yale B. Mitchel
JAMA. 2005;293(1):37.
EXTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes
William L. Isley
JAMA. 2005;293(1):37-38.
EXTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes
Michael H. Davidson
JAMA. 2005;293(1):38.
EXTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes—Reply
James A. de Lemos, Michael A. Blazing, Robert M. Califf, Stephen D. Wiviott, and Eugene Braunwald
JAMA. 2005;293(1):38-39.
EXTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes—Reply
Steven E. Nissen
JAMA. 2005;293(1):39.
EXTRACT | FULL TEXT  

Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial
James A. de Lemos, Michael A. Blazing, Stephen D. Wiviott, Eldrin F. Lewis, Keith A. A. Fox, Harvey D. White, Jean-Lucien Rouleau, Terje R. Pedersen, Laura H. Gardner, Robin Mukherjee, Karen E. Ramsey, Joanne Palmisano, David W. Bilheimer, Marc A. Pfeffer, Robert M. Califf, Eugene Braunwald, and for the A to Z Investigators
JAMA. 2004;292(11):1307-1316.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.